KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) EBIT (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed EBIT for 15 consecutive years, with $131.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT rose 225.26% year-over-year to $131.7 million, compared with a TTM value of $501.6 million through Dec 2025, up 383.56%, and an annual FY2025 reading of $501.6 million, up 383.56% over the prior year.
  • EBIT was $131.7 million for Q4 2025 at Alnylam Pharmaceuticals, down from $368.0 million in the prior quarter.
  • Across five years, EBIT topped out at $368.0 million in Q3 2025 and bottomed at -$258.0 million in Q3 2022.
  • Average EBIT over 5 years is -$72.6 million, with a median of -$131.3 million recorded in 2021.
  • The sharpest move saw EBIT tumbled 135.96% in 2024, then surged 578.49% in 2025.
  • Year by year, EBIT stood at -$194.6 million in 2021, then rose by 3.06% to -$188.6 million in 2022, then soared by 38.28% to -$116.4 million in 2023, then increased by 9.66% to -$105.2 million in 2024, then surged by 225.26% to $131.7 million in 2025.
  • Business Quant data shows EBIT for ALNY at $131.7 million in Q4 2025, $368.0 million in Q3 2025, and -$16.2 million in Q2 2025.